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S U M M A R Y
Background: Bacterial meningitis continues to be a serious, often disabling infectious disease. The aim of
this study was to assess the possibility that treatment inﬂuences the development of sequelae in
childhood bacterial meningitis.
Methods: Two thousand four hundred and seventy-seven patients aged 1 month to 14 years with acute
bacterial meningitis over a 32-year period were enrolled in the study. Data were collected prospectively
from the Meningitis Registry of a tertiary university teaching hospital in Athens, Greece. Treatment was
evaluated through univariate and multivariate analysis with regard to sequelae: seizure disorder, severe
hearing loss, ventriculitis, and hydrocephalus.
Results: According to the multinomial logistic regression analysis, there was evidence that penicillin, an
all-time classic antibiotic, had a protective effect on the occurrence of ventriculitis (odds ratio (OR) 0.17,
95% conﬁdence interval (CI) 0.05–0.60), while patients treated with chloramphenicol had an elevated
risk of ventriculitis (OR 17.77 95% CI 4.36–72.41) and seizure disorder (OR 4.72, 95% CI 1.12–19.96).
Cephalosporins were related to an increased risk of hydrocephalus (OR 5.24, 95% CI 1.05–26.29) and
ventriculitis (OR 5.72, 95% CI 1.27–25.76). The use of trimethoprim/sulfamethoxazole increased the
probability of seizure disorder (OR 3.26, 95% CI 1.08–9.84) and ventriculitis (OR 8.60, 95% CI 2.97–24.91).
Hydrocortisone was associated with a rise in hydrocephalus (OR 5.44, 95% CI 1.23–23.45), while a
protective effect of dexamethasone (OR 0.82, 95% CI 0.18–3.79) was not statistically signiﬁcant.
Conclusions: Current study ﬁndings suggest that the type of antimicrobial treatment for childhood
bacterial meningitis may inﬂuence in either a positive or a negative way the development of neurological
sequelae.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acute bacterial meningitis is an infection of the central nervous
system (CNS), often disabling, resulting in 170 000 deaths
worldwide annually.1 It is well known that the mortality of
untreated meningitis approaches 100%. Nevertheless, since the
advent of antimicrobial therapy it has become a curable disease.
The ﬁrst antibiotics that were used successfully for the treatment
of bacterial meningitis during World War II were sulfonamide and
penicillin. In the following decades a range of antimicrobials
became available, including ampicillin, chloramphenicol, ceftriax-
one, cefotaxime, and more recently vancomycin.2 Due to increas-
ing resistance to penicillin and cephalosporins, guidelines for the* Corresponding author. Tel.: +30 2410 565007; fax: +30 2410 565051.
E-mail address: xhatzi@med.uth.gr (C.S. Hadjichristodoulou).
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http://dx.doi.org/10.1016/j.ijid.2013.02.009empirical therapy of bacterial meningitis differ according to the
local prevalence of antimicrobial resistance. Third-generation
cephalosporins may be used as a ﬁrst choice for bacterial
meningitis beyond the neonatal period in areas of low prevalence
of bacterial resistance to cephalosporins. However, a combination
of vancomycin and third-generation cephalosporin is increasingly
preferred and is certainly the recommended treatment in areas
with reported penicillin resistance or cephalosporin-resistant
bacterial strains.3 Adjuvant corticosteroids are recommended,
however the beneﬁt of their use in the treatment of bacterial
meningitis in children remains unclear. Moreover, advances in
diagnostic techniques and critical care services have further
contributed to an improved outcome in acute bacterial meningitis.
Nevertheless, despite huge progress in the care provided, bacterial
meningitis is still a source of substantial morbidity. Between 10%
and 20% of survivors develop permanent sequelae such as epilepsy,
mental retardation, or hearing impairment.4 The long-termses. Published by Elsevier Ltd. All rights reserved.
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who have suffered bacterial meningitis beyond the age of 6 months
has been investigated, with some evidence of a possible impact.5
Several risk factors have been related to the development of
sequelae, such as the causative organism, age, gender, duration of
illness before admission, physical examination ﬁndings at admis-
sion (depressed level of consciousness, focal neurologic deﬁcits,
convulsions, absence of petechiae), laboratory ﬁndings (low
cerebrospinal ﬂuid (CSF) glucose, high CSF protein, positive blood
culture), etc.6–9 The effectiveness and safety of the various types of
therapy in patients with acute bacterial meningitis have also been
evaluated.4,10–12 The aim of our study was to assess the possibility
that the type of treatment is a risk factor for sequelae in childhood
bacterial meningitis by using data from the Meningitis Registry.
2. Materials and methods
2.1. Study population
We used data from the Meningitis Registry of the Infectious
Diseases Department of Agia Soﬁa Children’s Hospital in Athens,
Greece. The study population consisted of children admitted with
acute bacterial meningitis to this tertiary hospital from 1974 to
2005. For practical reasons the study was divided by date of
admission into three time-periods: period A (1974–1984), period B
(1985–1994), and period C (1995–2005); period C represents the
time after the introduction of the conjugate Haemophilus inﬂuenzae
type b (Hib) vaccine. Cases were patients aged 1 month to 14 years
with clinical and laboratory ﬁndings consistent with acute
bacterial meningitis. Children with recurrent or tuberculous
meningitis were excluded from the analysis. A registry form was
completed for each case upon discharge of the patient, and follow-
up visits were made for up to 3 months after discharge. The
detailed methodology concerning the Meningitis Registry, includ-
ing study setting, data collection, inclusion and exclusion criteria,
and case deﬁnitions, have been described elsewhere.13,14
2.2. Deﬁnitions
‘Treatment’ included parenteral administration of one or more
of the following antibiotics: ampicillin, penicillin, cephalosporins
(cefotaxime, ceftriaxone, ceftazidime), gentamicin, chlorampheni-
col, trimethoprim/sulfamethoxazole, and sulfonamide. ‘Adjuvant
corticosteroid therapy’ was deﬁned as the receipt of dexametha-
sone or hydrocortisone intravenously on the ﬁrst day of
hospitalization. ‘Sequelae’ was deﬁned as the presence of severe
hearing loss, ventriculitis, hydrocephalus, or seizure disorder
during a follow-up period of 3 months. The rate of sequelae was
estimated among survivors. The term ‘severe hearing loss’ was
applied to a hearing threshold of >80 dB, as assessed by an
audiologist. ‘Ventriculitis’ was diagnosed by intraventricular
paracentesis (in the ﬁrst years of the study) and later by
intraventricular ultrasound and computed tomography of the
head. ‘Hydrocephalus’ was deﬁned as an abnormal increase in head
circumference or dilation of the ventricular system as detected by
imaging studies. ‘Seizure disorder’ was deﬁned as any convulsive
disorder of any type that did not exist before the onset of
meningitis and was present during and after hospitalization.
2.3. Data analysis
Data were analyzed using Epi-Info (version 3.5.3, CDC, Atlanta)
and SPSS 19.0 (IBM SPSS Inc., USA). For the univariate analysis,
the Chi-square test or Fisher’s exact test was used to explore the
association between treatment risk factors and sequelae; therelative risk (RR) and the 95% conﬁdence interval (95% CI) were
also calculated.
For the multivariate analysis, multinomial (polytomous)
logistic regression analysis was used to evaluate whether
treatment as a risk factor differed across sequelae, controlling
for other risk factors. The multinomial logistic regression model
was constructed comparing risks among each of the sequelae
(hydrocephalus, seizure disorder, severe hearing loss, and ven-
triculitis) with no sequelae. Sequelae were used as dependent
variables and all of the risk factors were included in the model as
independent variables. Other important prognostic factors such as
etiology (pneumococcal meningitis, meningococcal meningitis),
age below 6 months, time period, and the interactions between
steroids, type of pathogen, and type of antibiotic were also
included in the multinomial logistic model to explore the
independent association of antibiotics with neurologic sequelae.
Odds ratios (ORs) and the 95% CI were calculated for the
independent variables. To test the adequacy of the model a
goodness-of-ﬁt test was used. In univariate analysis, due to
multiple comparisons, a p-value less than 0.01 was considered
statistically signiﬁcant, whilst in multivariate analysis a p-value
less than 0.05 was considered statistically signiﬁcant.
3. Results
In total, 2477 bacterial meningitis cases were recorded over the
32 years. The causative organisms most commonly included
Neisseria meningitidis, Hib, and Streptococcus pneumoniae, with
mean annual incidence rates of 8.9, 1.7, and 1.3 cases per 100 000
population, respectively. During the same period 2.2% (55/2477) of
patients were conﬁrmed with bacterial meningitis due to other
pathogens (Streptococcus spp, Staphylococcus spp, Escherichia coli,
Klebsiella pneumoniae, Proteus spp, Salmonella spp, Pseudomonas
aeruginosa, Brucella melitensis, Acinetobacter, Enterobacter cloacae,
Mycoplasma pneumoniae, and Rickettsia spp), while 29.6% (732/
2477) of bacterial meningitis cases were of unknown pathogen.
The median age of those patients was 2.0 years with an
interquartile range (IQR) of 0.5–5.0, and 58.7% were male. The
median duration of symptoms before hospital admission was 24 h
(IQR 24–48 h). The majority of patients presented with fever
(1158/1242, 93.2%), meningeal signs (1212/1477, 82.1%), vomiting
(1193/2074, 57.5%), and headache (871/1112, 78.3%). Less
common manifestations included hemorrhagic rash (967/2466,
39.2%), bulging fontanel (416/918, 45.3%), and seizures (337/1777,
19.0%). The median CSF white cell count was 1468  106 cells/l,
median CSF glucose was 42.0 mg/dl, and median CSF protein was
90.0 mg/dl. More detailed clinical and laboratory characteristics of
the study population can be found in previous publications.13–15
The estimated case fatality rate (CFR) from all causes was 3.8% (95/
2477, 95% CI 3.1–4.7).
The rate of sequelae among survivors was estimated to be 3.3%
(83 episodes occurred in 73/2207 patients, 95% CI 2.6–4.2). The
morbidity rate was increased during the period 1993–1996 and the
years 2003 and 2005 (Figure 1). Severe hearing loss was detected in
only 1.0% of patients (23/2235 patients, 95% CI 0.7–1.6),
ventriculitis in 1.0% of patients (22/2243 patients, 95% CI 0.6–
1.5), hydrocephalus in 0.5% of patients (12/2243, 95% CI 0.3–1.0),
and a seizure disorder was diagnosed in 1.1% of patients (24/2247,
95% CI 0.7–1.6).
The in-hospital treatment of patients who survived bacterial
meningitis included ampicillin (1350 patients), penicillin (1102
patients), chloramphenicol (1353 patients), gentamicin (192
patients), and cephalosporins (265 patients). About seventy-one
percent (70.9%) of patients received a combination of antibiotics.
The most popular combination was penicillin with chlorampheni-
col (42.5%), followed by ampicillin with chloramphenicol (25.2%),
Figure 1. Mortality and morbidity rates over the 32-year study period (1974–2005).
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gentamicin (2.8%). Combinations with gentamicin were mainly
used in the ﬁrst period of the study, while those with
chloramphenicol were popular choices in periods A and B.
Figure 2 displays the use of ampicillin, penicillin, chloramphenicol,
and cephalosporins over the 32-year study period. As shown in
Figure 2, penicillin consumption increased from 1980 and it was
used systematically until 2004, while a gradual replacement by
cephalosporins started in 1998.
Adjuvant corticosteroids were administered to 1602 children
(67.3%) overall, dexamethasone being the most commonly used
corticosteroid (administered to 69.4% of corticosteroid recipients).
Figure 3 shows the use of dexamethasone and hydrocortisone
during the study period. Dexamethasone use was decreased during
the period 1984–1987, while hydrocortisone use was increased
during that period.
The results of the univariate analysis concerning therapeutic
predictors of sequelae are presented in Table 1. According to this
analysis the use of gentamicin was associated with seizure
disorder (RR 5.66, 95% CI 2.43–13.17), with ventriculitisFigure 2. Antibiotic use over the 32-(RR 9.74, 95% CI 4.19–22.63), and with hydrocephalus (RR 5.39,
95% CI 1.64–17.72). Trimethoprim/sulfamethoxazole was associ-
ated with an elevated risk of ventriculitis (RR 10.21, 95% CI 4.40–
23.72), seizures (RR 3.99, 95% CI 1.60–10.00), and hydrocephalus
(RR 5.68, 95% CI 1.73–18.70). Chloramphenicol administration was
found to be related to the development of seizures (RR 4.48, 95% CI
1.33–15.02). No other associations were identiﬁed between the
other antibiotics and sequelae.
Since pneumococcal meningitis is more frequently associated
with sequelae, the above analysis was also conducted selecting
only the pneumococcal meningitis cases. The results found were
similar to those of the previous analysis: gentamicin was
associated with seizure disorder (RR 7.45, 95% CI 2.56–21.68)
and with hydrocephalus (RR 10.21, 95% CI 1.56–67.04).
Additionally a univariate analysis was conducted exploring the
association between corticosteroids and any of the sequelae in
each pathogen category. It was observed that in cases of
pneumococcal meningitis, dexamethasone was associated with a
lower risk of hydrocephalus, seizure disorder, and severe hearing
loss, but without statistical signiﬁcance. In contrast, hydrocortisoneyear study period (1974–2005).
Figure 3. Dexamethasone and hydrocortisone use over the 32-year study period (1974–2005).
K. Theodoridou et al. / International Journal of Infectious Diseases 17 (2013) e707–e713e710was associated with an increased risk of all of the sequelae subtypes,
without statistical signiﬁcance as well.
The results of the polytomous models are presented in
Table 2. An elevated risk of seizure disorder (OR 4.72, 95% CI
1.12–19.96) and ventriculitis (OR 17.77, 95% CI 4.36–72.41)
was found among the patients who received chloramphenicol.
The use of cephalosporins was associated with an elevated
risk of hydrocephalus (OR 5.24, 95% CI 1.05–26.29) and
ventriculitis (OR 5.72, 95% CI 1.27–25.76). Trimethoprim/
sulfamethoxazole was associated with an increased risk of
hydrocephalus (OR 6.79, 95% CI 1.74–26.43), seizure disorder
(OR 3.26, 95% CI 1.08–9.84), and ventriculitis (OR 8.60, 95% CI
2.97–24.91). Penicillin was associated with a lower risk of
ventriculitis (OR 0.17, 95% CI 0.05–0.60). Ampicillin neither
proved to be protective nor increased the risk of the
development of any sequelae. Hydrocortisone was associated
with a signiﬁcant rise in hydrocephalus (OR 5.44, 95% CI 1.26–
23.45). On the other hand, the protective effect of dexameth-
asone for hydrocephalus (OR 0.82, 95% CI 0.18–3.79) was not
statistically signiﬁcant.
According to the multinomial logistic regression analysis,
pneumococcal meningitis was an independent risk factor for the
development of seizure disorder (OR 10.47, 95% CI 3.24–33.82), as
well as age below 6 months (OR 20.20, 95% CI 5.55–73.55).
Moreover, bacterial meningitis in infancy was independently
related to an increased risk of hydrocephalus (OR 7.40, 95% CI 1.75–
31.37). Still, the risk of severe hearing loss was decreased in cases
of meningococcal meningitis (OR 0.21, 95% CI 0.06–0.71) in
comparison to other pathogens.
Finally, no signiﬁcant interactions were identiﬁed between
steroids, type of pathogen, and type of antibiotic for the risk of
neurologic sequelae.
4. Discussion
Antibiotic treatment for childhood bacterial meningitis, includ-
ing third-generation cephalosporins, as well as conventional
antibiotics such as penicillin and chloramphenicol, has been
proven generally safe and effective.16,17 Nevertheless the use of
adjuvant corticosteroids is still debated. The patient groups that
are going to gain from their use need to be clearly identiﬁed,
balancing beneﬁts vs. disadvantages.18,19
The current study explored the association of treatment for
childhood bacterial meningitis with the development of short-
term sequelae using data from a large series of patients over anextended time-period. It is the ﬁrst time that antibiotics used for
the treatment of bacterial meningitis have been compared with
regard to neurologic sequelae using a multinomial logistic
regression model including other important parameters (patho-
gen, age of the patient, time period, etc.). According to our ﬁndings
patients treated with chloramphenicol had an elevated risk of
seizure disorder and ventriculitis. Chloramphenicol inhibits
protein synthesis in bacteria and acts as a bacteriostatic drug
for most pathogens, although it may be bactericidal to certain
species such as N. meningitidis, S. pneumoniae, and Hib. It readily
reaches therapeutic concentrations in the CSF, where values are
approximately 60% of those in plasma,20 and it tends to accumulate
in brain tissue.21 Occasionally results with chloramphenicol used
for pneumococcal meningitis are unsatisfactory, because some
strains are inhibited but not killed. Moreover, its administration
has been implicated in the development of encephalopathy22 and
bilateral optic neuritis.23 A possible explanation for the neurotox-
icity of chloramphenicol may be either treatment failure or toxic
accumulation of the drug in brain tissue.
Another drug that is no longer used for bacterial meningitis –
trimethoprim/sulfamethoxazole – was found to increase the
probability of hydrocephalus, seizures, and ventriculitis. It acts
through inhibition of folic acid synthesis and causes bacteriostasis.
The drug readily enters the CSF, and unfortunately the margin
between toxicity for bacteria and humans is narrow. It has been
reported to be associated with encephalopathy, psychosis,
hallucinations, and aseptic meningitis, although the exact mecha-
nism is unknown.24,25
Interestingly in our study, third-generation cephalosporins
were related to an increased risk of hydrocephalus and ventricu-
litis. They act through the inhibition of cell wall synthesis and their
effect is bactericidal. In a Cochrane review16 of randomized
controlled trials (RCTs), the effectiveness and safety of ceftriaxone
or cefotaxime were compared with conventional treatment with
penicillin or ampicillin–chloramphenicol in patients with commu-
nity-acquired acute bacterial meningitis. No clinically important
difference between ceftriaxone or cefotaxime and conventional
antibiotics was identiﬁed. Concerning poor outcomes, the review
shows a statistically signiﬁcant increase only in the risk of diarrhea
between the groups with the third-generation cephalosporins. On
the other hand, evidence is accumulating that the administration
of cephalosporins is related to neurotoxicity.26 Clinical presenta-
tions can range from encephalopathy to non-convulsive status
epilepticus.27 Previous CNS disease, renal impairment, excess
dosage of medication, and young age decrease the threshold for
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antibiotic in the brain tissue rather than the concentrations in CSF
are predictive of neurotoxicity.28 One possible mechanism of
action is provided through electrophysiological data. They suggest
a direct antagonistic action of cephalosporins on the GABAA
receptor complex, responsible for their epileptogenic effects,
similar to other beta-lactam antibiotics.29 However, the precise
pathophysiology remains poorly understood.
It was found in the current study that the use of penicillin did
not increase the risk of any sequelae, and it was also found
protective for ventriculitis. A possible explanation of this ﬁnding
could be related to the superior bioavailability of the drug in the
course of CNS inﬂammation. This ﬁnding underlines the impor-
tance of an all-time classic and low cost antibiotic, which is still the
ﬁrst choice for sensitive strains of meningococci and pneumococci.
Interestingly the epileptogenic effect of penicillin through inhibi-
tion of GABAA receptors
28 was not shown in our series.
Hydrocortisone was associated with a rise in hydrocephalus.
This ﬁnding may be attributed to the fact that historically
hydrocortisone was administered to severely compromised
patients on admission. The use of hydrocortisone for bacterial
meningitis was studied in the early seventies,30,31 but it was soon
replaced with dexamethasone, which proved to have a more
potent anti-inﬂammatory effect. In our study, dexamethasone was
not found to be protective for the development of hearing loss, but
we had some indications of a protective effect for the development
of hydrocephalus, without statistical signiﬁcance. In 1988 Lebel
et al., in a placebo-controlled study, were the ﬁrst to show a
beneﬁcial effect of dexamethasone on hearing impairment in
childhood bacterial meningitis.32 Since then multiple clinical and
experimental studies have tried to clarify this issue.33–37 According
to a Cochrane review,18 corticosteroids prevent hearing loss in
children with bacterial meningitis (RR 0.74, 95% CI 0.62–0.89),
especially children with meningitis caused by H. inﬂuenzae type b
(RR 0.34, 95% CI 0.20–0.59) and children in high-income countries
(RR 0.67, 95% CI 0.46–0.97). A second meta-analysis that included
ﬁve trials, published after 2001, concluded that dexamethasone
did not affect mortality, as well as hearing loss or other neurologic
sequelae.38 The available evidence shows that dexamethasone use
prevents hearing impairment in Hib meningitis only, whereas
there is not enough evidence in favor of the systematic use of
steroids in pneumococcal meningitis and no evidence for
meningococcal cases.12 Moreover, the risk of other neurological
sequelae does not appear to be reduced in patients with bacterial
meningitis who receive adjuvant corticosteroids.18 We have to
acknowledge that better conclusions could be achieved if we had
data on the speciﬁc reason for the prescription of the corticoste-
roids.
Additional studies will be necessary after the introduction of
newer pneumococcal conjugate vaccines, which are expected to
signiﬁcantly change the epidemiology of bacterial meningitis,
especially in those areas where pneumococcal meningitis is the
leading cause of acute bacterial meningitis. Some evidence already
shows that invasive disease from vaccine serotypes is going to be
severely decreased.39 In this case the need for dexamethasone
should be re-evaluated, while at the same time monitoring should
be done for a shift to non-vaccine serotypes.
In conclusion, the current study ﬁndings provide some evidence
that the type of antimicrobial treatment for childhood bacterial
meningitis may inﬂuence the development of neurological
sequelae. The use of penicillin was found to have a protective
effect, while chloramphenicol, cephalosporins, and trimethoprim/
sulfamethoxazole increased the risk of neurological sequelae.
Concerning steroids, hydrocortisone increased the risk of hydro-
cephalus, while a protective effect of dexamethasone was not
statistically signiﬁcant. The current study ﬁndings in combination
Table 2
Multivariate analysis of treatment and other prognostic factors for sequelae in childhood bacterial meningitisa
Treatment and
other prognostic
factors
Sequelae subtypes
Hydrocephalus Seizure disorder Severe hearing loss Ventriculitis
OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value
Ampicillin 0.44 (0.10–1.92) 0.276 0.65 (0.20–2.09) 0.472 0.63 (0.17–2.39) 0.498 0.64 (0.16–2.46) 0.512
Penicillin 1.19 (0.23–6.17) 0.838 1.01 (0.29–3.57) 0.989 0.40 (0.11–1.55) 0.186 0.17 (0.05–0.60) 0.006
Cephalosporins 5.24 (1.05–26.29) 0.044 1.49 (0.34–6.54) 0.599 1.47 (0.38–5.60) 0.577 5.72 (1.27–25.76) 0.023
Gentamicin 1.85 (0.41–8.44) 0.426 2.14 (0.66–6.91) 0.205 1.27 (0.24–6.78) 0.783 2.85 (0.90–8.99) 0.075
TMP/SMX 6.79 (1.74–26.43) 0.006 3.26 (1.08–9.84) 0.036 1.32 (0.29–5.99) 0.718 8.60 (2.97–24.91) <0.001
Chloramphenicol 7.62 (0.79–73.92) 0.080 4.72 (1.12–19.96) 0.035 1.31 (0.39–4.42) 0.664 17.77 (4.36–72.41) <0.001
Dexamethasone 0.82 (0.18–3.79) 0.796 1.21 (0.41–3.55) 0.729 1.22 (0.49–2.99) 0.670 2.31 (0.71–7.53) 0.166
Hydrocortisone 5.44 (1.26–23.45) 0.023 2.06 (0.63–6.75) 0.231 0.80 (0.21–3.07) 0.746 2.50 (0.68–9.20) 0.167
S. pneumoniae 3.27 (0.77–13.90) 0.108 10.47 (3.24–33.82) <0.001 1.42 (0.36–5.60) 0.612 2.17 (0.47–9.92) 0.319
N. meningitidis 0.33 (0.06–1.81) 0.200 1.35 (0.41–4.52) 0.623 0.21 (0.06–0.71) 0.012 0.54 (0.16–1.83) 0.322
Age <6 months 7.40 (1.75–31.37) 0.007 20.20 (5.55–73.55) <0.001 0.63 (0.19–2.13) 0.456 2.63 (0.89–7.78) 0.081
Period Ab 0.61 (0.14–2.62) 0.511 0.75 (0.24–2.32) 0.620 0.50 (0.15–1.65) 0.258 3.09 (0.75–12.72) 0.118
OR, odds ratio; CI, conﬁdence interval; TMP/SMX, trimethoprim/sulfamethoxazole.
a This analysis is based on 88.7% of the study population due to missing values. The adequacy of the model results was examined by the likelihood ratio Chi-square statistic,
a goodness-of-ﬁt test (p = 0.999).
b Period A: 1974–1984.
K. Theodoridou et al. / International Journal of Infectious Diseases 17 (2013) e707–e713e712with those of other reports in the literature suggest a causative
relationship between antimicrobial therapy and the outcome of
bacterial meningitis. Future studies may further elucidate these
ﬁndings.
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